Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Boosted by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 39.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 319,176 shares of the biopharmaceutical company’s stock after acquiring an additional 90,380 shares during the period. Horizon Kinetics Asset Management LLC owned 0.05% of Royalty Pharma worth $8,142,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Corient Private Wealth LLC grew its position in shares of Royalty Pharma by 86.0% during the fourth quarter. Corient Private Wealth LLC now owns 46,249 shares of the biopharmaceutical company’s stock worth $1,180,000 after acquiring an additional 21,383 shares during the last quarter. Rakuten Securities Inc. grew its position in Royalty Pharma by 160.5% in the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 1,003 shares in the last quarter. Jupiter Asset Management Ltd. bought a new position in Royalty Pharma in the 4th quarter valued at about $4,950,000. EverSource Wealth Advisors LLC grew its position in Royalty Pharma by 24.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 4,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 818 shares in the last quarter. Finally, AGF Management Ltd. bought a new position in Royalty Pharma in the 4th quarter valued at about $2,513,000. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $32.77 on Monday. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $18.89 billion, a price-to-earnings ratio of 22.60, a PEG ratio of 2.31 and a beta of 0.47. The firm has a 50-day moving average of $31.58 and a two-hundred day moving average of $28.56.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.69%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date was Friday, February 21st. Royalty Pharma’s dividend payout ratio is presently 60.69%.

Analysts Set New Price Targets

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus target price of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.